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Abstract 
Background: TLR4/MD-2 complex-mediated MyD88-dependent activation of NF-κB and Akt promotes tumor-
associated immunosuppression in epithelial ovarian cancer (EOC) via induction of immunesuppressive cytokines and 
indoleamine 2,3-dioxygenase (IDO). Atractylenolide I (AO-1) is a naturally occurring sesquiterpene lactone known to 
change the conformational ensemble of human MD-2 on EOC cells. This study examined the modulation by AO-1 of 
TLR4/MD-2 complex-mediated MyD88/NF-κB signaling.
Methods: The expression and activation of NF-κB, Akt and IDO1 by MyD88+ EOC SKOV3 cells was determined using 
western blot; the TLR4/MD-2 complex on SKOV3 cells and the phenotype of T lymphocytes were determined using 
flow cytometry; IDO activity was evaluated by measuring l-kynurenine; Immunesuppressive cytokines were detected 
using ELISA; T‐cell proliferation to mitogen stimulation was assessed by MTT assay; the cytotoxicity of lymphocytes 
and NK cells was measured using LDH-cytotoxicity assay.
Results: AO-1 could down-regulate expression of TLR4/MD-2 complex, resulting in downregulation of MyD88/NF-κB 
signaling and activation of NF-κB, Akt and IDO1 and secretion of IL-6, TGF-β1, VEGF and IL-17A by EOC SKOV3 cells, 
and further reduce increased levels of regulatory T cells (Treg cells) and improve decreased proliferative response and 
antitumor cytotoxicity of T lymphocytes exposed to EOC SKOV3 cell supernatant.
Conclusion: AO-1 may reverse EOC cell-mediated immunosuppression through blocking TLR4/MD-2 complex-medi-
ated MyD88/NF-κB signaling.
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Background
Epithelial ovarian cancer (EOC) is the fifth leading cause 
of death among women with gynecologic malignancies 
[1]. Recent research has suggested that EOC is capable of 
escaping the immune system due to interaction between 
cancer cell and host immune cell in tumor microenviron-
ment. EOC cells constitute an immunosuppressive envi-
ronment that promotes tumor growth, progression, and 
immune evasion [2]. Cancer-induced immunosuppres-
sion is an intractable problem as it impairs the response 
to immunotherapy [3]. Increasing evidence suggests that 
cancer cells have usurp acquired many properties charac-
teristic of immune cells, allowing them to communicate 
and more importantly, modulate the immune responses 
and escape immune elimination for its own survival and 
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Toll-like receptors (TLRs) constitute an important cel-
lular signal pathway which induces tumor immnuosup-
pression and chemoresistance. The activation of TLRs 
signaling in tumor cells induces the production of vari-
ous immunosuppressive cytokines to impair dendritic 
cells (DCs) ability to stimulate antitumor T cells and to 
induce various immunosuppressive cells, then resulting 
in immune incompetence in the tumor microenviron-
ment [5, 6]. Therefore, it is important to elucidate molec-
ular mechanism of the immunosuppression by EOC, and 
to develop strategies to restore immunocompetence in 
EOC patients.
It has been shown that EOC cells bear TLR4 and 
MyD88, an adapter coupling TLR4 and that TLR4/
MyD88 signaling induces the synthesis of immunosup-
pressive cytokines and facilitates tumor progression and 
immune evasion [7]. MyD88 is expressed in approxi-
mately 70 % of patients with EOC and has been identified 
as an independent factor of poor prognosis [8, 9]. Sign-
aling through TLR4 requires concomitant expression of 
an accessory protein, myeloid differentiation protein-2 
(MD-2), which is functionally an essential component 
of the TLR4 signaling complex with an indispensable 
role for the initiation of TLR4/MyD88 signaling [10–
12]. TLR4/MD-2 complex is required for activation of 
MyD88-dependent NF-κB pathway [13–15] in MyD88 
expressing EOC cells. NF-κB is one of the main intracel-
lular pathways mediating the induction of immunosup-
pressive cytokine and enzyme expression following TLR4 
activation [16]. It has been found that EOC cells consti-
tutively express interleukin (IL)-6, IL-4, IL-10, IL-17A, 
VEGF, TGF-β1 and indoleamine 2,3-dioxygenase [17–
29]. These immunosuppresants produced by EOC cells 
represents a significant mechanism of tumor immune 
escape and tolerance through increasing Treg cells and 
suppressing NK cell function, T cell activation and pro-
liferation [2, 30]. Thus, the effective immunotherapy for 
EOC may be achieved by reversing EOC cell-mediated 
immunosuppression.
Atractylenolide I (AO-1) is a natural sesquiterpene lac-
tone extracted from Atractylodes macrocephala Koidz 
[Family: Compositae] which possesses immune regula-
tion in Chinese traditional medicine [31], and is known 
to antagonize TLR4-mediated production of proinflam-
matory cytokines including NO, TNF-α, IL-6, IL-1β, 
and VEGF in some immune cells [32]. Previously we 
showed that AO-1 can significantly reduce expression 
of TLR4 and MD-2 by EOC cells [33]. These data sug-
gest that AO-1 may make the molecular conformation 
of MD-2 changed and interrupt the assembly of TLR4/
MD-2 complex, and then block MyD88-dependent sign-
aling pathway. However, it is unknown whether MyD88 
act autonomously or require a TLR4/MD-2 complex to 
engage these downstream pathways. Thus, research into 
immunotherapy targeting TLR4/MD-2 complex-medi-
ated MyD88/NF-κB and Akt pathways of EOC cells will 
probably become focused on an approach to combination 
immunotherapy that simultaneously intensify anti-tumor 
immune responses while reversing tumor immune sup-
pression. In this study, we evaluated the role of TLR4/
MD-2 complex in the immunosuppression caused by 
human EOC, and the immune modulation of AO-1 tar-
geting TLR4/MD-2 complex-mediated MyD88-depend-
ent activation of NF-κB through blocking MD-2 binding 
to TLR4. Our primary findings showed that AO-1 could 
inhibit TLR4/MD-2 complex-mediated MyD88-depend-
ent activation of NF-κB and Akt, and reduce the expres-
sion of immunosuppressive molecules by SKOV3 cells 
and the level of Treg cells induced by the supernatant 
of SKOV3 cells, and enhance proliferative response and 
cytotoxicity of T lymphocytes. These findings suggest 
that AO-1 could modulate EOC cell-mediated immuno-
suppression by targeting TLR4/MD-2 complex on EOC 
cells and that AO-1 is a potential inhibitor of TLR4/
MD-2 complex. Therefore, TLR4/MD-2 complex is an 
attractive target for the development of effective EOC 
immunotherapeutic strategies for EOC patients whose 




Atractylenolide I, (4aS,8aS)-3,8a-dimethyl-5-methylidene- 
4a,6,7,8-tetrahydro-4H-benzo[f][1] benzofuran-2-one (CAS 
No.73069-13-3, MF C15H18O2, m.w. (g/mol) 230.3022, 
HPLC 98  %) was purchased from Chengdu Best-Reagent 
Co. Ltd. (Chengdu, China); lipopolysaccharide (LPS), phy-
tohemagglutinin (PHA), MTT (3-[4,5-dimethylthiazol-
2-yl]- 2,5-diphenyl tetrazolium bromide), l-kynurenine 
and 4-dimethylaminobenzaldehyde were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA); the rabbit poly-
clonal antibodies to NF-κB p65, phospho-NF-κB p65 (S536)
(ab76302), Akt and phospho-Akt (S129) (ab133458), anti-
GAPDH antibody [EPR6256] (ab128915) and anti-TLR4/
MD-2 complex antibody[7E3](FITC)(ab105855) were pur-
chased from Abcam plc.(Cambridge, MA, USA); Perox-
idase-Conjugated AffiniPure Goat Anti-Rabbit IgG was 
purchased from ZSGB-BIO, Inc. (Beijing,China); ELISA kits 
for IL-6, IL-4, IL-10, IL-17A, TGF-β1 and VEGF were pur-
chased from R&D Systems, Inc. (Minneapolis, MN 55413, 
USA); CD4-FITC/CD8-PE/CD3-PerCP (Catalog Number: 
340298) for determining CD4/CD8/CD3 counts of T lym-
phocytes and FoxP3 Staining Kit—FoxP3-PE/CD4-FITC/
CD25-APC (Catalog Number: 560133) for determining 
counts of Treg cells were purchased from Becton, Dick-
inson and Company (BD Biosciences, USA); CytoTox 96® 
Page 3 of 12Liu et al. J Transl Med  (2016) 14:104 
Non-Radioactive Cytotoxicity Assay (G1781) was pur-
chased from Promega Corporation (Madison, WI, USA).
Cell lines and cultures
Human EOC SKOV3 cell line (MD-2+/TLR4+/MyD88+, 
derived from the ascites of a patient with advanced, met-
astatic EOC and resistant to most cytotoxic drugs) and 
human K562 cell line (lacking the MHC, derived from a 
female patient with chronic myeloid leukemia) and Raji cell 
line (MHC+, derived from B-lymphocyte of a male patient 
with Nigerian Burkett’s lymphoma) were purchased from 
the Committee on Type Culture Collection of Chinese 
Academy of Sciences (CTCCCAS, Shanghai, China). Cell 
lines were maintained in RPMI-1640 medium (GIBCO) 
supplemented 10 % heat inactivated fetal calf serum (FCS), 
2 mmol/L l-glutamine, 100 U/mL penicillin and 40 IU/mL 
gentamycin (complete RPMI-1640 medium) at 37 °C in a 
humidified atmosphere of 5 % CO2 and 95 % air. Subcon-
fluent cells (80 %) were passaged with a solution contain-
ing 0.25 % trypsin and 0.5 mmol/L EDTA. Cell lines were 
tested for mycoplasma and confirmed to be negative.
Preparation of monocyte‑free lymphocytes
The peripheral blood mononuclear cells (PBMCs) were 
prepared from heparinized venous blood of a healthy 
female adult donor by centrifugation over a Ficoll-
Hypaque(1.077  g/mL) gradient. PBMCs were resus-
pended in complete RPMI-1640 medium, and incubated 
in 60-mm glass culture flasks at 37  °C in a 5  % CO2. 
After 4 h, the nonadherent cells devoid of contaminating 
monocytes, i.e., lymphocytes, were harvested to be used 
for this study.
Preparation of SKOV3 cell supernatants
1 ×  106 SKOV3 cells were seeded into 6-well (Corning 
Costar) in a final volume of 2  mL and preincubated at 
37  °C in a 5 % CO2 for 24 h, then replaced with RPMI-
1640 medium containing 2  % FCS with addition of the 
specified concentration of AO-1, LPS and 1-MT and 
incubated at 37 °C in a 5 % CO2 for 48 h, and the culture 
supernatants were harvested by centrifugation at 1000g 
for 10 min at 4 °C min, and stored at −80 °C until use for 
analysis.
Western blot
SKOV3 cells were lysed in RIPA buffer [1 % Triton X-100, 
150  mmol/L NaCl, 1  mmol/L EGTA, 50  mmol/L Tris–
HCl, 0.1  % sodium dodecyl sulfate (SDS), 1  % sodium 
desoxycholate and phenylmethylsuphonyl fluoride 
(PMSF)]. Proteins separated by SDS-PAGE were electro-
transfered on polyvinylidene difluoride (PVDF) mem-
branes. After blocking, the membrane was incubated 
with the primary antibody at 4 °C overnight, and washed 
three times and incubated with Peroxidase-Conjugated 
AffiniPure Goat Anti-Rabbit IgG secondary antibody 
(1:100,000 dilution) at 37 °C for 1 h, and then developed 
in an electrochemiluminescence (ECL) detection system 
(ImageQuant™LAS500,GE). GAPDH antibody as load-
ing control was used to normalize the levels of protein 
detected.
ELISA
Enzyme-linked immunosorbent assay (ELISA) was used 
to determine cytokine IL-6, IL-10, IL-4, IL-17A, TGF-β1 
and VEGF according to the manufacturer’s protocols of 
ELISA kits. Briefly, 100 μL of the culture supernatant of 
SKOV3 cells, the standard or the control was added to 
each well in 96-well ELISA plate (R&D) and incubated 
for 2 h at room temperature. Each well was aspirated and 
washed three times with Wash Buffer, then 200 μL of the 
antibody specific for cytokine conjugated to horserad-
ish peroxidase was added to each well, incubated for 2 h 
at room temperature, aspirated and washed three times 
with Wash Buffer. 200 μL of the substrate solution to each 
well, and incubated in the dark for 20 min at room tem-
perature, and then 50 μL of the stop solution was added 
to each well. The absorbance was determined using Infi-
nite M200 Pro TECAN-Reader at 450 nm, with the cor-
rection at wavelength set 570 nm.
Measurement of l‑kynurenine
IDO activity was evaluated by measuring the levels of 
tryptophan metabolite, l-kynurenine, present in the 
supernatant of SKOV3 cells with Ehrlich’s reagent (1.2 % 
4-dimethylaminobenzaldehyde in glacial acetic acid). 
Briefly, 150  μL of the culture supernatants of SKOV3 
cells were added to each well of a 96-well round-bot-
tom culture plate, and after addition of 10 μL 30 % (v/v) 
trichloroacetic acid to each well, the plate was incubated 
for 30 min at 50 °C to hydrolyze N-formylkynurenine to 
kynurenine, and centrifuged at 1500g for 10 min; 100 μL 
of supernatant was transferred to the corresponding wells 
of a 96-well flat-bottom plate and mixed with 100  μL 
of freshly prepared Ehrlich’s reagent and incubated for 
10  min at room temperature. Absorbance was read at 
492  nm using Infinite M200 Pro TECAN-Reader, with 
a blank that containing culture media only and purified 
l-kynurenine (0–100 μmol/L) was used as a standard.
Flow cytometry for TLR4/MD‑2 complex expression 
by SKOV3 cells
TLR4/MD-2 complex expression by SKOV3 cells were 
determined using TLR4/MD-2 complex staining kit [7E3]
(FITC) according to the manufacturer’s protocols. Briefly, 
SKOV3 cells treated with LPS (1 μg/mL) and AO-1 (10, 50 
and 100 μmol/L) for 6 h were harvested with 0.25 % trypsin 
Page 4 of 12Liu et al. J Transl Med  (2016) 14:104 
digestion and washed three times with PBS containing 2 % 
FCS (FCS) by centrifugation at 500g for 5 min at 4 °C, and 
resuspended in 100 μL of antibody diluent, and incubated 
with FITC anti human TLR4/MD-2 complex mAb for 
30 min at 4 °C, then centrifuged at 500g for 5 min at 4 °C 
and the supernatants were removed and fixed with 4  % 
paraformaldehyde in PBS (10  mmol/L, pH 7.4) for over-
night at 4 °C, and washed twice with washing buffer by cen-
trifugation at 500g for 5 min at 4 °C. The stained cells were 
resuspended in 1 mL of FACS buffer and were analyzed on 
FACSCanto II Flow Cytometer (Becton–Dickinson).
Flow cytometry for the phenotype of T lymphocytes
The phenotype of T lymphocytes exposed to SKOV3 cell 
supernants for 24 h was assessed by flow cytometry (FCM). 
For CD3+/CD4+/CD8+ counts, 20  μL TriTEST CD4-
FITC/CD8-PE/CD3-PerCP antibody was added to a test 
tube, and then 20 μL of lymphocyte suspension containing 
1 × 106 cells was added to the tube, and mixed gently. After 
incubation in the dark for 15  min at room temperature, 
450 μL of 1 × BD FACS lysing solution was added to the 
tube. Gating for T-cells was performed using CD3+ cells. 
Cell Quest software (BD Bioscience) was used to deter-
mine the percentage of CD4+ and CD8+ cells in the CD3+ 
cells; For CD4+/CD25+/Foxp3+ Treg cells, 20 μL of FITC 
Mouse Anti-Human CD4 and 20  μL APC Mouse Anti-
Human CD25 were added to a test tube, and then 100 μL 
of lymphocytes suspension containing 1  ×  106 cells was 
added to the tube, mixed fully and incubated in the dark for 
30 min at 2–8  °C, washed once with 2 mL of pre-cooling 
PBS by centrifugation at 1000 rpm for 5 min at 4 °C. One 
milliliter of 1  ×  Fix/Perm buffer was added to the tube, 
and incubated in the dark for 40–50 min at 2–8  °C, then 
washed twice with 2  mL of 1  ×  Perm/Wash buffer. The 
cells were resuspended in 100 μL of 1 × Perm/Wash buffer, 
and 100  μL of PE Mouse Anti-Human Foxp3 was added, 
and then incubated in the dark for 40–50 min at 2–8  °C. 
The cells were washed twice with 2 mL of 1 × Perm/Wash 
buffer, the supernatant was discarded, and then 350  μL 
of PBS was added to the tube. Gating for T-cells was per-
formed using CD4+ cells. Cell Quest software (BD Biosci-
ence) was used to determine the percentage of CD25+/
Foxp3+ Treg cells in the CD4+ cells.
SKOV3 cell supernatant‑exposed lymphocyte responses 
to mitogen stimulation
Inhibition of T-cell proliferation by SKOV3 cell super-
natant was assessed by measuring T-cell proliferation 
response to stimulation with 10 μg/mL PHA. Briefly, lym-
phocytes (2 × 104/well) were added to 96-well U bottom 
plate in the presence of the supernatants of SKOV3 cells 
treated with or without AO-1 and 1-MT, and RPMI-1640 
medium containing 2  % FCS as the control. After 72  h 
incubation, 20 μL of MTT (5 mg/mL) was added into each 
well but not into the blank well and incubated at 37 °C, 5 % 
CO2 for 4 h. The plate was centrifuged at 1000g for 5 min 
and the supernatant was removed, and 200 μL of DMSO 
was added into each well to solubilize the formazan crys-
tals, and then the solution was transferred into 96-well 
flat bottom plate and absorbance was measured at 595 nm. 
Proliferation response is calculated as the fomula:
SKOV3 cell supernatant‑exposed lymphocyte cytotoxicity
Cytotoxicity mediated by lymphocytes were measured 
using CytoTox 96® Non-Radioactive Cytotoxicity Assay 
according to the manufacturer’s protocols. In brief, lym-
phocytes were preincubated with the supernatants of 
SKOV3 cells or treated with AO-1 or 1-MT for 24 h and 
were harvested and resuspended in complete RPMI-1640 
medium. Lymphocytes (effector, 1 × 104/well) and Raji or 
K562 cells (target, cells/well according to effector:target 
ratios of 1:1, 5:1 and 10:1) were planted into a round-bot-
tom 96-well culture plate in a final volume of 100 μL/well, 
and mixed gently and centrifuged at 250g for 5 min, and 
then incubated at 37  °C, 5 % CO2 for 24 h. Fifty microli-
tre of the supernatant from each well was transfer to the 
corresponding well of a flat-bottom 96-well enzymatic 
assay plate, and then 50  µL of the CytoTox 96® Reagent 
was added to each well of the plate and incubated at room 
temperature, protected from light, for 30 min, and 50 µL of 
the Stop Solution to each well of the plate was added, then 
absorbance was measured at 490  nm. The percent cyto-
toxicity for each effector:target cell ratio is calculated as: 
% Cytotoxicity = [(Experimental
−Effector Spontaneous− Target Spontaneous
)
/(















AO‑1 attenuasstes expression of TLR4/MD‑2 complex 
by SKOV3 cells
Based on our previous work [33], we propose that bind-
ing of AO-1 should inhibit LPS-induced formation of 
TLR4/MD-2 complex on the surface of SKOV3 EOC cells 
which express TLR4 and MD-2. FCM analysis showed 
that SKOV3 cells constitutively express TLR4/MD-2 
complex (2.81 ± 0.41 %) (Fig. 1A-a), and that the expres-
sion of TLR4/MD-2 complex (13.14 ±  1.18  %) was sig-
nificantly increased following exposure of SKOV3 cells 
to LPS, compared to the corresponding control (P < 0.05) 
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(Fig. 1B); the constitutive and LPS-induced expression of 
TLR4/MD-2 complex (from 2.81 ± 0.41 to 1.21 % ± 0.21 
and from 13.14  ±  1.18 to 4.13  ±  0.45  %, respectively) 
were significantly decreased following exposure of 
SKOVE cells to AO-1, as compared to the control and 
LPS alone (P < 0.05) (Fig. 1A-b, A-c and A-d; B).
AO‑1 down‑regulates expression and activation of NF‑kB 
and Akt by SKOV3 cells
It is important to prove a cross-relationship between 
activation of TLR4/MD-2 complex and the resultant 
immunosuppression through constitutively activated 
NF-κB and Akt signalings in EOC. To address this issue, 
we examined whether AO-1 could affect the expres-
sion and activation of NF-kB p65 and Akt which are 
required for up-regulation of immunosuppressive fac-
tors in MyD88+EOC cells. Western blot showed that LPS 
(1 μg/mL) significantly (P < 0.05) increased expression of 
NF-kB p65, p- NF-kB p65, Akt and p-Akt, and that AO-1 
(100 μmol/L) alone or combined with LPS (1 μg/mL) sig-
nificantly (P < 0.05) down-regulated expression of NF-kB 
p65, p- NF-kB p65, Akt and p-Akt by SKOV3 cells in 
time-dependent manner (Fig. 2a, b).
AO‑1 down‑regulates expression of IDO1 by SKOV3 cells 
and level of l‑kynurenine in SKOV3 cell supernatant
As shown in Fig. 2c, SKOV3 cells constitutively expressed 
IDO1 protein, and the protein expression of IDO1 was 
significantly increased (P  <  0.05) following exposure of 
SKOV3 cells to LPS but decreased significantly (P < 0.05) 
following exposure of SKOV3 cells to AO-1 alone or 
combined with LPS, compared to the corresponding 
control. The IDO1 activity was confirmed by the meas-
urement of l-kynurenine, the breakdown product of 
tryptophan (Fig.  2c). The level of l-kynurenine in the 
supernatants was significantly (P  <  0.05) increased fol-
lowing expoure of SKOV3 cells to LPS but remarkably 
(P < 0.05) decreased following expoure of SKOV3 cells to 
AO-1 alone or or combined with LPS, compared to the 
corresponding control. Addition of 1-MT (25  μmol/L) 
resulted in a significant increase in level of l-kynurenine 
in the supernatant of SKOV3 cells (P < 0.05).
AO‑1 attenuates production of immunosuppressive 
cytokines in SKOV3 cell supernatant
To prove whether the down-regulation of NF-kB and Akt 
activation by AO-1 decreases the production of immuno-
suppressive cytokines, the supernatants of SKOV3 cells 
exposed to LPS with or without addition of AO-1 for 
48  h were analyzed for IL-6, IL-17A, IL-10, IL-4, TGF-
β1 and VEGF by ELISA. As shown in Fig. 3, SKOV3 cells 
constitutively secreted IL-6 (1539  ±  107.73  pg/mL), IL-
17A (116 ± 29 pg/mL), IL-10 (47.8 ± 3.35 pg/mL), IL-4 
(12.6 ± 0.63 pg/mL), TGF-β1 (1205 ± 84.35 pg/mL) and 
VEGF (75  ±  5.25  pg/mL). In response to LPS (1.0  μg/
mL), the levels of IL-6 (2618  ±  130.9  pg/mL), IL-17A 
(226  ±  11.3  pg/mL), TGF-β (1425  ±  73.25  pg/mL) and 
VEGF (85  ±  4.08  pg/mL) were remarkably increased, 
compared to the control (P  <  0.05); Whereas AO-1 not 
only decreased the constitutive but also LPS-induced 
levels of IL-6, IL-17A, TGF-β1 and VEGF (P  <  0.05) 
Fig. 1 FCM analysis for MD-2/TLR4 complex. A Representative FCM diagrams of MD-2/TLR4 complex detection. SKOV3 cells were treated with 
AO-1(100 μmol/L) alone or combined with LPS (1 μg/mL) respectively. Next, MD-2/TLR4 complex was detected with FCM as described under 
“Methods” section. B Inhibition of AO-1 on LPS-induced MD-2/TLR4 complex in SKOV3 cells. All experiments were performed in triplicate, and data 
are expressed as mean ± SD (n = 3). Error bars represent SD of replicate data points. *P < 0.05, compared to the control
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(Fig. 3a–d), but did not impact the levels of IL-10 and IL-4 
(Fig. 3e, f ), as compared to the corresponding control.
AO‑1 modulates the subpopulations of T lymphocytes 
exposed to SKOV3 cell supernatant
As shown in Fig. 4a, CD4+/CD8+ ratios of T cells were 
1.34  ±  0.17 and 0.86  ±  0.12, respectively, and higher 
than that (1.81 ± 0.24) in the control following exposure 
of lymphocytes to the supernatants of SKOV3 cells or 
treated with LPS, but were 1.36 ± 0.18, 1.43 ± 0.19 and 
1.74 ±  0.23, respectively following exposure of lympho-
cytes to the supernatants of SKOV3 cells treated with 
AO-1 (10, 50 and 100  μmol/L); As shown in Fig.  4b, 
CD4+CD25+Foxp3+ levels of T cells were 10.26 ± 0.62, 
10.81 ± 0.65 and 10.83 ± 0.72 %, respectively, and were 
higher than that (7.34 ± 0.51 %) in the control following 
exposure of lymphocytes to the supernatants of SKOV3 
cells or treated with LPS and 1000 pg/mL of TGF-β1 as 
a positive control, but were 4.75 ± 0.33, 3.55 ± 0.24 and 
2.67  ±  0.24  %, respectively following exposure of lym-
phocytes to the supernatants of SKOV3 cells treated 
with AO-1 (10, 50 and 100  μmol/L). AO-1 significantly 
improved the CD4+/CD8+ ratio but decreased the 
CD4+/CD25+/Foxp3+ levels of T cells in a concentra-
tion-dependent manner, as compared to the correspond-
ing control (P < 0.05).
AO‑1 improves proliferative response of T lymphocytes 
exposed to SKOV3 cell supernatant
As shown in Fig.  5a, the proliferative responses of T 
lymphocytes were reduced following the supernatant of 
SKOV3 cells but significantly improved following expo-
sure of lymphocytes to the supernatant of SKOV3 cells 
treated with or 1-MT, compared to the corresponding 
control (P < 0.05). The T lymphocytes exposed to super-
natant of SKOV3 cells had significantly lower responses 
to PHA and lost the ability to respond to mitogens in the 
PHA stimulation system.
Fig. 2 Western blot detection for expression of involved proteins by EOC cells. a and b SKOV3 cells were treated with AO-1 alone or combined with 
LPS as indicated concentration for indicated time, and the expression of NF-κB p65, p-NF-κB p65, Akt and pAkt was determined by western blot as 
described under “Methods” section. c Represents IDO1 expression and IDO activity (l-kynurenine release). All experiments were performed in tripli-
cate and data are expressed as mean ± SD (n = 3). Error bars represent SD of replicate data points. *P < 0.05, compared to the control
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AO‑1 improves antitumor cytotoxicity of T lymphocytes 
exposed to SKOV3 cell supernatant
As shown in Fig.  5b, c, the killing effects of T lympho-
cytes on K562 and Raji cells were significantly impaired 
following exposure of lymphocytes to the supernatant 
of SKOV3 cells but significantly ameliorated following 
exposure of lymphocytes to the supernatant of SKOV3 
cells treated with AO-1 or 1-MT, compared to the cor-
responding control (P < 0.05).
Discussions
A major obstacle for the development of effective immu-
notherapy is the ability of tumors to escape the immune 
system. Cancer is the initiator of evil in the immuno-
suppressive microenvironment. To be effective, EOC 
immunotherapy may be necessary to reversion of cancer 
cell-mediated immunosuppression. Presently EOC immu-
notherapy remains behind. Characterization of EOC 
cells that express TLR4/MD-2 and MyD88 have helped 
to confirm the dynamic role of the  immunosuppres-
sive microenvironment in promoting cancer metastasis 
and recurrence. One of the major reasons for the insuf-
ficient response to current immunotherapies is thought 
to be tumor-mediated immunosuppression, which is trig-
gered by oncogene activation and dysregulated signaling 
in cancer cells. However, the mechanisms leading to the 
production and induction of immunosuppressive mol-
ecules are not fully understood. Some anti-inflammatory 
phytochemicals appear to exhibit activity in modulating 
the tumor microenvironment. Phyto-active compounds 
Fig. 3 Measurement of cytokines in the culture supernatant of SKOV3 cells. Detection of cytokines in the culture supernatant of SKOV3 cells treated 
with AO-1 alone or combined with LPS using ELISA as described under “Methods” section. a–f represents IL-6, IL-17A, VEGF, TGF-β1, IL-4 and IL-10, 
respectively. All experiments were performed in triplicate, and data are expressed as mean ± SD (n = 3). Error bars represent SD of replicate data 
points. *P < 0.05, compared to the control
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have been shown to induce apoptosis, and prevent or 
delay chemotherapy-resistance. Specifically curcumin and 
quercetin as a ligand of MD-2 or TLR4 potently repress 
TLR4/MyD88/NF-кB signal pathway and inhibit immu-
nosuppressive cytokine production, and suppress ovarian 
cancer cell metastasis. The experiments described herein 
aimed to clarify the relationship between the immuno-
suppression and TLR/MD-2 complex-mediated activation 
of MyD88/NF-κB signaling in human EOC, as well as 
to develop an immune modulatory therapy targeting 
TLR/MD-2 complex. Human EOC cells usurp or hijack 
TLR4/MyD88 signaling pathway that considerably acti-
vates NF-κB and Akt pathways, which trigger expression 
of immunosuppressive molecules resulting in immune 
incompetence in the tumor microenvironment [6, 13]. 
TLR4/MD-2 complex plays a crucial role for activation of 
Fig. 4 Detection of subpopulation of T cells and Treg cells of lymphocytes. Detection of subpopulation of T cells and Treg cells of lymphocytes 
exposed to the culture supernatant of SKOV3 cells treated with AO-1 alone or combined with LPS using FCM assay as described under “Methods” 
section. a FCM diagrams of CD3+/CD4+/CD8+ of T cells, and b FCM diagrams of CD4+CD25+FoxP3+ of Treg cells. All experiments were performed 
in triplicate, and data are expressed as mean ± SD (n = 3). Error bars represent SD of replicate data points. *P < 0.05, compared to the control
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MyD88/NF-κB pathway in human EOC cells. In this study, 
we have shown that AO-1 could depress LPS-induced 
increased expression of TLR4/MD-2 complex by blocking 
assembly of TLR4/MD-2 (Fig. 1A, B), and down-regulate 
LPS-induced IDO1 in EOC SKOV3 cells (Fig. 2c). LPS is 
an agonist of TLR4/MD-2 complex, and MD-2 is requisite 
for the activation of TLR4/MD-2 complex and directly 
bridges the two components of the multimer resulting in 
TLR4 coupling MyD88 [14–16]. AO-1 is an antagonist of 
TLR4/MD-2 complex, just like Eritoran [34, 35], and may 
block MD-2-bridged TLR4 homodimer coupling with 
MyD88, resulting in inhibition of MyD88-dependent sign-
aling pathway that activates NF-κB signaling. A functional 
TLR-4/MyD88/NF-κB pathway confers to EOC cell the 
capacity to respond to TLR4 ligands and enhances NF-κB 
activity and cytokine production, and plays a central role 
in the control of immunosuppression in human EOC 
[16]. We found that AO-1 down-regulated LPS-induced 
the phosphorylation of NF-κB p65 and Akt (Fig.  2a, b), 
suggesting that the activation of NF-κB p65 and Akt is 
dependent on TLR4/MD-2 complex in SKOV3 EOC cells. 
EOC cells are able to induce expression of FoxP3 in CD4+/
CD25+ T regulatory cells and exhibit suppressive ability 
in activated naïve T cells by producing soluble multiple 
cytokines. Constitutive expression of IL-6, TGF-β1, IL-
17A, VEGF, IL-4, IL-10 and IDO by tumor cells as a major 
component of immune escape and immunosuppression 
in human EOC. It has been demonstrated that the ascites 
IL-6 of EOC patients influences the local immunity and 
contributes to lower fraction of NK cells and CD8+/CD3+ 
cells [25]; Both of TGF-β1 and IL-17 induce an increase 
in frequencies of Treg cells (CD4+CD25+FoxP3+) and 
the number of FoxP3+ cells is positively correlated with 
the immunoexpression of IL-17 and TGF-β1. Similar to 
TGF-β1, the supernatant derived from SKOV3 cells could 
convert part of freshly isolated CD4+/CD25− T cells into 
CD25+ population with characters as CD4+/CD25+/
FoxP3+ Treg cells. Knockdown TGF-β1 gene increases 
the immunogenicity of human EOC cells and impairs the 
tumorigenic ability of human EOC cells [36, 37]. The role 
of VEGF in tumor angiogenesis has been well character-
ized, nevertheless, it is also known to have an immuno-
suppressive activity besides its angiogenic role and to 
promote tumor immune escape by impairing DC matura-
tion and antitumour T cell activation in the tumor micro-
environment. Recent studies show that VEGF significantly 
reduces the cytotoxic activity of T cells and directly 
suppresses T cell activation via VEGF receptor type 2, 
and also inhibits LPS-induced maturation of DCs [38, 
39]. In patients with EOC, EOC cells are able to synthe-
size and secrete IL-10 and IL-4. It has been documented 
that proinflammatory stimuli IL-1β and TNF-α enhance 
IL-10 secretion, but LPS and IL-6 have no influence on 
the release of IL-10 [19], whereas IL-10 and IL-4 do not 
influence elevated FoxP3 expression induced by EOC cell 
culture supernatant [40]. These results demonstrate that 
Fig. 5 Detection of proliferative response and cytotoxicity of T cells. 
a Represents the detection of proliferative response of T cells with 
PHA stimulation using MTT assay as described under “Methods” 
section, and b, c the detection of T cells cytotoxicity against K562 
and Raji cells following exposure of lymphocytes to the supernatant 
of SKOV3 cells treated with AO-1 or 1-MT using LDH release assay as 
described under “Methods” section, respectively. All experiments were 
performed in triplicate, and data are expressed as mean ± SD (n = 3). 
Error bars represent SD of replicate data points. *P < 0.05, compared 
to the control
Page 10 of 12Liu et al. J Transl Med  (2016) 14:104 
AO-1 could down-regulate expression of IL-6, TGF-β1, 
IL-17A and VEGF (Fig. 3a–d) but not IL-4 and IL-10 by 
SKOV3 cells (Fig.  3e, f ), and reduce frequencies of Treg 
cells following exposure of lymphocytes to the superna-
tant of SKOV3 cells alone or treated with LPS, suggesting 
that the expression of IL-6, TGF-β1, IL-17A and VEGF is 
dependent on TLR4/MD-2/MyD88/NF-κB and Akt sign-
aling pathways. miR-155 has been shown to influence 
CD4 T cell, regulatory T cell and effector and effector 
memory CD8 T cell differentiation [40]. The Foxp3 target 
miR-155 contributes to the development of regulatory T 
cells. miR-155 expression is strongly induced by inflam-
matory cytokines [41, 42]. Human epithelial ovarian car-
cinoma cell-derived cytokines may cooperatively affect on 
miR-155 expression of T-cells, contributing to changes of 
T cell phenotype and function [43].
It is known that IDO plays a critical regulatory role in 
EOC progression [28, 44]. IDO, as an inducer and ampli-
fier of Treg cell functions, activates regulatory T cells. 
Evidence emerges indicating that IDO possibly promotes 
tumor immune escape by inducing an immunoregu-
latory T cell phenotype at a systemic level, and alloge-
neic T cell proliferation is inhibited by IDO-expressing 
cancer cells [45]. IDO  can both deplete tryptophan in 
local tissue microenvironments and generate kynure-
nine, a tryptophan catabolite. Kynurenine is known to 
induce the conversion of naïve CD4+/CD25− T cells 
into highly suppressive CD4+/CD25+/Foxp3+ Treg cells 
and to inhibit the proliferative response of T cells to 
mitogen stimulation. Treg cell is known to induce IDO 
expression in DCs and to change from inflammatory to 
regulatory DCs, which can in turn enlarge the Treg cells 
compartment by tryptophan catabolism [46]. IDO pro-
motes the peritoneal dissemination of EOC by inhibiting 
NK cell accumulation in tumors and promoting angio-
genesis. IDO gene silencing in EOC SKOV3 cells trans-
fected with siRNA reduced the constitutively expresses 
IDO and release of kynurenine into the supernatant, 
and suppressed tumor progression and peritoneal dis-
semination and enhanced the sensitivity of cancer cells 
to NK cells in the tumor microenvironments. Down-
regulation of IDO controls human EOC progression by 
activating NK cells [28]. The constitutive IDO expression 
in human EOC is sustained by an IL-6 autocrine signal-
ing loop that is critical for IDO-mediated immunosup-
pression in human EOC [29]. These data represented 
more common phenomenon of immunosuppression 
of tumor microenvironment in human EOC. The tryp-
tophan metabolite kynurenine inhibits cell growth and 
induce apoptosis. T cells are particularly sensitive to this 
stress, which easily suppresses their function [46]. In 
IDO-expressing tumors, IDO promotes local tryptophan 
degradation and depletion, resulting in T-cell function 
suppression, leading to local immunotolerance. In the 
present study, we showed that AO-1 downregulated IDO 
protein expression (Fig.  2c) and functional activity by 
EOC cells and increased the proliferative response of T 
cells to mitogen stimulation (Fig. 5a) and the sensitivity 
of cancer cells to T cells and NK cells in vitro (Fig. 5b, 
c). The possibility cannot be excluded that TLR4/MD-2 
complex expression is involved in EOC immunosuppres-
sion through such an IDO-mediated mechanism. These 
findings indicate that the AO-1 targeting TLR4/MD-2 
complex modulates IDO-mediated immunosuppression 
in SKOV3 cells.
Conclusion
We have demonstrated that TLR4/MD-2 complex-medi-
ated activation of MyD88/NF-kB is the major mechanism 
for immunosuppression through induction of immu-
nosuppressive molecules and generation of immuno-
suppressive T cells by human EOC SKOV3 cells. TLR4/
MD-2 complex inhibitor such as AO-1 may be useful for 
reversal of immunosuppressive conditions in EOC, which 
may increase responses to immunotherapy and chemo-
therapy. This study suggested that TLR4/MD-2 complex 
could potentially serve as a target in reversion of the 
immunosuppressive microenvironment of human EOC 
and the combination immunotherapy targeting TLR4/
MD-2 complex may be an attractive strategy for MyD88-
expressing EOC treatment. Certainly, the role of TLR4/
MD-2 complex for activation of MyD88/NF-κB signaling 
needs to be further studied in a variety of ovarian cancer 
cell lines of different phenotypes, and even in vivo study.
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